<table cellpadding="0pt" cellspacing="0pt" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="50%"></col>
<col width="50%"></col>
<tbody>
<tr>
<td colspan="2" stylecode="Rrule Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">Inhibitors of CYP3A4 and CYP2D6</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>The concomitant use of oxycodone hydrochloride tablets  and CYP3A4 inhibitors can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of oxycodone hydrochloride tablets and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of oxycodone is achieved <content stylecode="italics">[see <linkhtml href="#ID_e39cb1f8-1af0-4dc3-898b-8bd540a5c341">Warnings and Precautions (5.4)].</linkhtml>
</content> After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the oxycodone plasma concentration will decrease <content stylecode="italics">[see <linkhtml href="#ID_e0eae10b-f26c-474d-9d60-671fd9229851">Clinical Pharmacology (12.3)],</linkhtml>
</content> resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to oxycodone.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>If concomitant use is necessary, consider dosage reduction of oxycodone hydrochloride tablets until stable drug effects are achieved. Monitor patients for respiratory depression and sedation at frequent intervals.</paragraph>
<paragraph>If a CYP3A4 inhibitor is discontinued, consider increasing the oxycodone hydrochloride tablets dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir).</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">CYP3A4 Inducers</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>The concomitant use of oxycodone hydrochloride tablets and CYP3A4 inducers can decrease the plasma concentration of oxycodone <content stylecode="italics">[see <linkhtml href="#ID_e0eae10b-f26c-474d-9d60-671fd9229851">Clinical Pharmacology (12.3)]</linkhtml>
</content>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to oxycodone <content stylecode="italics">[see <linkhtml href="#ID_e39cb1f8-1af0-4dc3-898b-8bd540a5c341">Warnings and Precautions (5.12)].</linkhtml>
</content>
</paragraph>
<paragraph>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the oxycodone plasma concentration will increase <content stylecode="italics">[see <linkhtml href="#ID_e0eae10b-f26c-474d-9d60-671fd9229851">Clinical Pharmacology (12.3)],</linkhtml>
</content> which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>If concomitant use is necessary, consider increasing the oxycodone hydrochloride tablets dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider oxycodone hydrochloride tablets dosage reduction and monitor for signs of respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Rifampin, carbamazepine, phenytoin</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[see <linkhtml href="#ID_e39cb1f8-1af0-4dc3-898b-8bd540a5c341">Warnings and Precautions (5.5)].</linkhtml>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Serotonergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome <content stylecode="italics">[see <linkhtml href="#ID_4f3c4fac-922a-49fa-abf6-e5f841bddff0">Adverse Reactions (6.2)].</linkhtml>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue oxycodone hydrochloride tablets if serotonin syndrome is suspected.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[see <linkhtml href="#ID_e39cb1f8-1af0-4dc3-898b-8bd540a5c341">Warnings and Precautions (5.2)].</linkhtml>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>The use of oxycodone hydrochloride tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. </paragraph>
<paragraph>If urgent use of an opioid is necessary, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>phenelzine, tranylcypromine, linezolid</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Mixed Agonist/Antagonist Opioid Analgesics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>May reduce the analgesic effect of oxycodone  hydrochloride tablets and/or may precipitate withdrawal symptoms.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Avoid concomitant use</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Butorphanol, nalbuphine, pentazocine, buprenorphine</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Muscle Relaxants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Oxycodone may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of oxycodone hydrochloride tablets and/or the muscle relaxant as necessary.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Diuretics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Monitor patients for signs of dismissed diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Anticholinergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>The concomitant risk of anticholinergic drugs may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule ">
<paragraph>Monitor patients for signs of urinary retention or reduced gastric motility when oxycodone hydrochloride tablets are used concurrently with anticholinergic drugs.</paragraph>
</td>
</tr>
</tbody>
</table>